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Abstract: Brain tumors are the leading cause of cancer-related deaths in children, and
medulloblastoma is the most prevalent malignant childhood/pediatric brain tumor. Providing
effective treatment for these cancers, with minimal damage to the still-developing brain, remains
one of the greatest challenges faced by clinicians. Understanding the diverse events driving tumor
formation, maintenance, progression, and recurrence is necessary for identifying novel targeted
therapeutics and improving survival of patients with this disease. Genomic copy number alteration
data, together with clinical studies, identifies c-MYC amplification as an important risk factor
associated with the most aggressive forms of medulloblastoma with marked metastatic potential.
Yet despite this, very little is known regarding the impact of such genomic abnormalities upon the
functional biology of the tumor cell. We discuss here how recent advances in quantitative proteomic
techniques are now providing new insights into the functional biology of these aggressive tumors, as
illustrated by the use of proteomics to bridge the gap between the genotype and phenotype in the
case of c-MYC-amplified/associated medulloblastoma. These integrated proteogenomic approaches
now provide a new platform for understanding cancer biology by providing a functional context to
frame genomic abnormalities.
Keywords: medulloblastoma; MYC; quantitative proteomics
1. Introduction
Medulloblastoma (MB) is the most common pediatric malignant brain tumor and one of the
leading causes of brain cancer deaths in children. Current therapy for high-risk medulloblastoma
involves aggressive treatments that often leave survivors with significant neurological and intellectual
disabilities due to the effects of these nonspecific cytotoxic therapies on the developing brain [1].
Extensive intertumoral heterogeneity is found in medulloblastoma, with at least four distinct molecular
variants identified using genomic profiling techniques [2–4]. Significant differences in clinical outcome
among these subgroups demonstrate a need for subgroup-specific therapeutic strategies, yet a better
understanding of molecular drivers of disease is required before these efforts can be realized [2,5,6].
Although there is early promise for sonic hedgehog pathway (SHH) inhibitors in a subset of patients
with upstream mutations [7,8], there remain few targets for the other subgroups—particularly Group 3
tumors, which have the worst overall survival rates in patients.
2. Group 3 Medulloblastoma and c-MYC Amplification
Group 3 MB remain poorly understood despite accounting for over a quarter of medulloblastoma
cases and displaying significant recurrence and mortality rates (around 50% across multiple studies) [2,6].
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Although transcriptional profiling analysis identifies this subgroup based on an enrichment of genes
involved in GABAergic function, photoreceptor differentiation, and ribosomal biosynthesis, it fails to
identify any traditional druggable signaling pathways [2,9]. Furthermore, multiple next-generation
sequencing studies reveal few recurrent mutations in this subgroup except in distinct components of
the epigenetic machinery (e.g., KDM6A and ZMYM3), which are shared with Group 4 tumors [4,10,11].
All studies to date, including somatic copy number analysis across 1000 medulloblastoma genomes,
identify c-MYC copy number amplifications primarily confined to Group 3 tumors [12]. The
presence of these genomic amplifications represents a high-risk group associated with poor survival,
as highlighted through multivariable survival analysis of patients with Group 3 tumors [13].
3. Linking c-MYC Genomic Aberrations to Molecular Pathways Driving Tumor Behavior
Difficulties making inferences from genomic abnormality to cancer phenotype remain problematic
for all types of cancer. With regard to medulloblastoma, it is unclear how c-MYC amplification is driving
tumor aggressiveness. Increased c-MYC mRNA transcripts are observed in Group 3 tumors compared
to the SHH and Group 4 subgroups, yet there is no difference in comparison to tumors of the wingless
(WNT) subgroup (Figure 1). Unlike other subgroups, WNT tumors almost never harbor any MYC
amplifications [4,10,11] and increased transcript expression is attributed to MYC being a downstream
target of the WNT signaling pathway. Further, the near-total survival of the WNT subgroup (Figure 1)
tends to refute the idea that c-MYC overexpression alone is responsible for the poor survival observed
in Group 3 MB. This discrepancy in prognosis has been previously highlighted in other reviews [14]
and remains unresolved. Does this mean the aggressive phenotype of c-MYC-amplified tumors
within Group 3 MB is independent of c-MYC expression, or that the cellular context in which c-MYC
overexpression occurs is critical to phenotype determination? Of note, WNT medulloblastomas arise
from progenitor cells in the lower rhombic lip outside the cerebellum proper [15] as opposed to
Group 3 tumors which are demonstrated to originate from cerebellar stem cells or granule neuron
precursors [16,17]. We do in fact see a significant difference in c-MYC expression levels (p = 0.0056;
two tailed t-test equal variance) when we compare MYC-amplified and nonamplified tumors within
Group 3 tumors in humans (Figure 1), suggesting that c-MYC copy number amplifications may
indeed result in increased c-MYC transcript levels. In addition, amplification of homeobox proteins
orthodenticle homologue 2 (OTX2) is also identified in Group 3 MB [12]. Moreover, OTX2 and c-MYC
are frequently coexpressed at high levels in medulloblastoma and regulate many of the same genes,
indicating there might be a functional interaction between these two genes [18]. OTX2 is highly
expressed in the developing cerebellum, playing a critical role in the regional patterning of early
embryonic cells, but is silenced in adulthood. OTX2 has recently been shown to repress differentiation,
increase proliferation, and upregulate c-MYC in medulloblastoma cells [18–20].
The tumorigenic role of c-MYC in medulloblastoma is further complicated by RNA-Seq studies
showing persistent gene fusions involving the 5′ end of PVT1, a noncoding gene, which frequently
coamplifies with c-MYC [3]. In these studies, the majority of MYC-amplified tumors harbored
PVT1 fusions, which are proposed to arise as a result of chromothripsis [3]. Although PVT1 is
non-protein-coding, it is a host gene for four microRNAs, miR-1204–miR1207. Intriguingly, earlier
studies have implicated miR-1204, which is expressed at a higher level in c-MYC-amplified Group 3
tumors compared to the adjacent miR-1205 and miR-1206, as a candidate oncogene that enhances
oncogenesis in combination with MYC [21,22].
Taken together, the evidence supports a model in which MYC amplification drives an aggressive
phenotype in the permissive context provided by the cell of origin and in concert with other genomic
events such as OTX2 amplification and PVT1 fusion.
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found in Group 3 tumors and associated with poor survival (>50% survival), mRNA expression 
patterns are similar to that seen in the WNT subgroup (B) which has the best clinical outcome of all 
medulloblastoma subgroups. Increased gene transcripts are significantly associated with MYC-amplified 
Group 3 medulloblastomas when compared to nonamplified tumors from the same group (C); 
(Northcott et al., 2012 dataset under accession number GSE37385 [3]). 
4. Animal Models as a Platform to Understand c-MYC Function in Medulloblastoma 
The development of MYC-driven animal models of medulloblastoma has provided strong 
support for the role of c-MYC over-expression in the tumorigenesis of Group 3 MB. Initial 
independent animal models involving the induced overexpression of c-MYC in cerebellar stem cells 
or granule precursor cells have clearly shown that the resultant tumors not only display highly 
aggressive large cell anaplastic histology, but also are transcriptionally similar to Group 3 
medulloblastoma [16,17]. These models were instrumental in identifying possible therapeutic targets 
such as the PI3K/mTOR [17] and histone deacetylase (HDAC) pathways. Combination targeting of 
PI3K/mTOR and HDAC dramatically inhibited tumor growth in preclinical mouse models and 
human patient-derived xenografts (PDX) (Pei et al., unpublished data under preparation for 
Figure 1. (A) Summary for the proposed risk stratification of MYC-amplified tumors in Group 3
medulloblastoma. Interestingly, although c-MYC genomic amplifications are almost exclusively found
in Group 3 tumors and ass ciated with poor survival (>50% survival), mRNA expression patterns are
similar to that seen in the WNT subgroup (B) which has the best clinical outcome of all medulloblastoma
subgroups. Increased gene transcripts are significantly associated with MYC-amplified
Group 3 medulloblastomas when compared to nonamplified tumors from the same group (C);
(Northcott et l., 2012 dat set under accession umber GSE37385 [3]).
4. Animal M dels as a Platform to Understand c-MYC Function in Medulloblastoma
The development of MYC-driven animal models of m dulloblast ma has provided strong support
for the role of c-MYC over-expression in the tumorigenesis of Group 3 MB. Initial independent animal
models involving the induced overexpression of c-MYC in cerebellar stem cells or granule precursor
cells have clearly shown that the resultant tumors not only display highly aggressive large cell
anaplastic histology, but also ar transcriptionally similar to Group 3 medulloblastoma [16,17]. These
models were instrumental in identifying possible therapeutic targets such as the PI3K/mTOR [17]
and histone deacetylase (HDAC) pathways. Combination targeting of PI3K/mTOR and HDAC
dramatically inhibited tumor growth in preclinical mouse models and human patient-derived
xenografts (PDX) (Pei et al., unpublished data under preparation for submission.). Additionally,
MYC is not only required for tumor initiation, but also necessary for tumor maintenance. Inactivation
of c-MYC causes rapid tumor regression in mouse model, indicating that targeting c-MYC itself might
be an effective therapeutic strategy for this disease [17].
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5. The Role of Tumor Suppressor Protein Trp53 in Group 3 Medulloblastoma
An important caveat to the development of initial animal models for studying c-MYC function in
Group 3 MBs is that those mentioned above have all required the loss of Trp53 function to generate
c-MYC associated medulloblastoma phenotypes. This is particularly significant as Trp53 mutations
are not common in human Group 3 MB, and their absence was proposed to be indicative of other
significant cooperative genetic or molecular events that inhibit Trp53 function, potentiating tumor
initiation [14]. An intriguing new study demonstrating that MYC family amplifications and Trp53
pathway defects both emerged at relapse may provide support for this cooperativity [23] and may
imply that loss of Trp53 function is associated with tumor progression. These additional genomic
events found at relapse could not be detected at diagnosis, indicating that an acquisition of genetic or
epigenetic changes might occur after initial treatment. Whether this is the case with relapsing Group 3
medulloblastoma is unclear, but new animal models of MYC-driven tumors without disrupted Trp53
function are being developed and show homology with human Group 3 MB [24]. Further studies need
to determine whether MYC plays a different tumorigenic role in these various models and whether
they all result in similar tumor behavior.
In summary, although the data support c-MYC as a significant contributor to the phenotype and
maintenance of aggressive Group 3 MB, the exact mechanisms of its contribution remain incompletely
understood. This is further complicated by the fact that c-MYC regulates a variety of pathways, often
making it difficult to determine which molecular events are driving oncogenic behavior or are simply
downstream passenger events. There is a growing consensus among clinicians that the key molecular
mechanisms driving the aggressive recurrence of these tumors need to be clarified in order to rationally
improve therapy for these high-risk patients [25]. Thus, MYC biology provides a case study for the
most important challenge facing translational research in the genomic era. Given the incredible breadth
of genomic output, there is a tremendous challenge in determining which events are driving malignant
biology and thus should be the focus of therapeutic intervention. One concept that can provide insight
into this issue is the tenet that genomic events driving biology should project into the cellular proteome,
which comprises the bulk of the functional molecules of the cell.
Significant developments are being made in proteomic techniques and these are now providing
clinicians with unique insights into commonly studied cancers [26]. Researchers are realizing the
importance of proteomics as a platform to link the genome to phenotype, and a substantial investment
has been made in developing our understanding of the human proteome (see the draft map of the
human proteome project [27]). These techniques are also now providing promising new insights into
the study of c-MYC-amplified Group 3 medulloblastomas.
6. Advances in Proteomic Profiling of Cancers
Protein profiling in cancer has advanced tremendously from early techniques, almost half a
century ago, when starch gel electrophoresis was being used to determine globulin expression
profiles in serum from patients with myeloma and macroglobulinemia [28]. Possibly one of the
greatest advances in protein profiling was the introduction of polyacrylamide gels and isoelectric
focusing in the early 1960s that helped introduce two-dimensional polyacrylamide gel electrophoresis
(2D-PAGE) and allowed multiple numbers of proteins to be studied simultaneously. 2D-PAGE
studies have been extensively utilized in a wide range of studies covering nearly every cancer
type [29]. The ongoing research using 2D-PAGE has yielded significant results over the past decades
and helped identify several proteins as candidate prognostic markers of particular cancers [29,30].
Despite improvements in the 2D-PAGE approach, including fluorescence difference gel electrophoresis
(DIGE), this technique is often associated with a limited dynamic range, making it difficult to
profile low-abundance proteins [31]. Proteomic profiling using mass spectrometry, on the other
hand, continues to gather momentum, in large part due significant advances in instrumentation.
The development of matrix-assisted laser desorption ionization (MALDI) MS, for example, played a
pivotal role in protein expression maps of lymphoid neoplasms [32], and together with electrospray
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ionization (ESI), MS has allowed the quantitative analysis of increasing numbers of proteins from a
variety of cancers [33]. The next generation of liquid chromatography mass spectrometers (LC–MS),
with increased sensitivity and speed, together with high-resolution isoelectric focusing (HiRIEF),
enables deep proteome coverage and unbiased proteogenomic studies of cancer tissues [34].
Major concerns regarding proteomic techniques stem from the limited depth and reproducibility
of some of the early MS technologies. However, there have been significant contemporary
multi-laboratory collaborative studies, sponsored by the U.S. National Cancer Institute (NCI) and
the Human Proteome Organization (HUPO), which have examined the sources of irreproducibility
in MS-based proteomics [35,36]. These studies have demonstrated the high reproducibility across
laboratories and instrument platforms of MS-based assays of proteins in low microgram per milliliter
concentrations [35]. At present, optimized in-depth profiling techniques can identify proteins in
biological samples that span six or more logs of protein abundance [37]. Furthermore, great steps have
been made in not only identifying large numbers of proteins, but also in the ability to accurately and
reliably quantitate them. Currently considered the gold-standard for proteomic biology discovery,
metabolic stable isotopic labeling by amino acids in cell culture (SILAC) provides an accurate
means for quantitative protein analysis and has been extensively used in cell- and tissue-based
proteomics analyses.
7. Protein Quantification Using Stable Isotopic Labeling by Amino Acids in Cell Culture
SILAC was first described almost 10 years ago and is one of the most popular peptide labeling
techniques to date. The general concept is that relative and absolute quantification of a sample of
interest can be performed when comparing its MS intensity with that of a labeled peptide standard
introduced into the sample. To create the standard, peptides are metabolically labeled in culture by
introducing the isotope label into every protein during cell growth and division, generating a labeled
standard for every protein. This is done by growing parallel populations of the same cell line, one in
media containing a “light” (normal) amino acid and the other in media containing a “heavy” amino
acid. The heavy amino acid can contain a 13C instead of 12C, an 15N instead of 14N, or 2H instead of H.
When incorporated into a peptide, the heavy amino acid leads to a known mass shift (for example, 6 Da
in the case of 13C6-Arg) compared to the peptide with the normal (light) version of the amino acid [38].
In a simple experimental scheme, protein lysates from the two cell lines (heavy and light) are mixed in
equal amounts and their proteomes are measured using MS. A pair in the mass spectra will occur for
each peptide with the lower mass originating from the unlabeled sample and quantified as a relative
ratio to that of the heavy corresponding mass spectra, which originated from the labeled cell line.
When the heavy and light cell lines are exposed to different experimental conditions (e.g., hypoxia and
normoxia), the resulting alterations in the proteome can be measured. In a more translational setting,
SILAC has been used to compare microsomal fractions of more metastatic versus less metastatic
prostate-cancer cell lines [39], to identify novel prognostic markers of breast cancer progression [38],
and to quantify N-linked glycosylation in diffuse large B-cell lymphoma subtypes [40,41].
An extension of the SILAC protocol has been the creation of a reference standard from a mixture
of multiple SILAC-labeled cell lines (termed super SILAC) that better serves for quantifying proteins
(Figure 2) in complex tissues [38]. The use of a multiply sourced SILAC-labeled protein standard
increases quantification accuracy, as the combined SILAC reference better represents the total proteome
of a given tumor tissue despite expected intratumoral heterogeneity [38]. However, although this
method offers an ideal platform for large-scale relative quantification studies in tissue samples, the
limitations lie in the need to produce a reference standard that ensures significant and adequate
proteome coverage of all the proteins found in the tissue to be analyzed. Partially offsetting this
disadvantage is that the quantitated proteins must be present in both the reference standard and
the tumor tissue and are thereby necessarily tumor cellular proteins and not proteins derived from
contaminating stromal elements; this feature improves the signal-to-noise ratio.
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Figure 2. Schematic presentation of super-SILAC (stable isotopic labeling by amino acids in cell
culture) methodology. All proteins within different medulloblastoma primary/cell lines are isotopically
labeled, in vivo (using stable isotope labeling of amino acids in mammals: SILAM) or in vitro, through
incorporation of 13C6-Arg (MB—medulloblastoma). This causes a known shift of 6 Da in the mass
spectrometry spectra. The combined lysates of the isotopically labeled cultures are mixed (1:1 ratio)
with tumor lysates from different medulloblastoma tumor/cell samples resulting in two spectra profiles
per protein (separated by 6 Da). The protein of interest can now be quantified in the sample as a ratio
of the isotopically labeled protein in the same sample.
8. Proteomic Analysis of Medulloblastoma and c-MYC Function
Early proteomic profiling studies in medulloblastoma focused on biomarker identification in
cerebrospinal fluid (CSF) samples from pediatric patients [14,42]. Possible host responses to tumor
presence were detected when comparing tumor versus control samples using 2D-PAGE followed
by MALDI-time of flight MS analysis [42]. Independent studies using the same proteomic analysis
technique further highlighted the power MS-based proteomics to stratify surgical medulloblastoma
tissue samples based on histotype (classic versus desmoplastic/nodular) [43] or to study cancer stem
cell development within cultured medullospheres [44]. Not surprisingly, current research is rapidly
moving towards integrated genomic, bioinformatic, and proteomic techniques, which has recently
been used to provide novel insights into functional and signaling pathways in medulloblastoma
tumors harboring a 17p deletion and diffuse intrinsic pontine gliomas [45,46]. Recent work within
our group highlights the potential of new quantitative MS-based techniques to uncover the molecular
pathways and possible genetic drivers of c-MYC function in Group 3 medulloblastoma [47]. Taking a
super-SILAC-based approach, we constructed a novel medulloblastoma-specific reference standard
that demonstrated impressive quantification accuracy and efficiency when measuring proteins from
tumor cells across all the medulloblastoma subgroups. Distinct protein expression patterns between
c-MYC amplified versus nonamplified tumors were observed, suggesting significant metabolic
pathway differences between these groups [47].
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Our proteomic results showing increased expression of ribonucleoproteins (HNRNPs) associated
with spliceosome activity (HNRNPC, HNRNPA1, HNRNPA2, and PTB) is supported by earlier work
looking for c-MYC-dependent proteins in the medulloblastoma cell line D425Med [48]. Furthermore,
these proteome differences also partially overlap with those seen in the medulloblastoma transcriptome
studies [3]. Although never studied in the context of medulloblastoma, c-MYC is known to
regulate the expression of these proteins [49]. Importantly, these HNRNPs influence downstream
metabolism-related pathways through the altered expression of the pyruvate kinase M2 (PKM2)
isoform, which was also observed in our study, resulting in the Warburg effect. This may provide
a competitive advantage to the tumor cells by allowing increased survival under hypoxic and nutrient
poor conditions. Together, these proteomic results provide functional insight into c-MYC-driven
tumors and may help to explain the metastatic propensity of these tumor subtypes.
9. Characterizing Medulloblastoma Using MicroRNA–Proteomic Networks
MicroRNAs (miRNAs) are essential regulatory factors in the development of the central nervous
system and differentially expressed across different medulloblastoma subtypes [50,51]. Early studies
identified specific miRNA expression patterns that could distinguish differing medulloblastoma
molecular features, such as c-MYC overexpressing tumors, and may therefore provide interesting
insights into the factors regulating tumorigenesis [51]. Yet there is little known regarding how miRNAs
influence medulloblastoma tumor behavior.
A recent study conducted a specific analysis of proteins, miRNAs, and genes to characterize
human medulloblastoma stem-like cells (hMB-SLCs) [52]. These hMB-SLCs represent a significant
proportion of the tumor cell population and are associated with a poor prognosis [53]. Pathway
analysis (using the Genomatix Pathway System) of differentially expressed miRNAs together with
deregulated genes and proteins revealed exciting new subnetworks involved in the maintenance of
hMB-SLCs, including core pluripotency factors such as OCT4 and KLF4 [52]. Similarly, another study
showed that miRNA biogenesis regulates an important developmental transition in granule cells of
the cerebellum via the Sonic Hedgehog (Shh)–Patched (Ptch) signaling pathway, which significantly
alters medulloblastoma growth phenotypes [54].
Emerging studies clearly highlight the differential expression of miRNAs in different
medulloblastoma subgroups, and proteomic analysis is providing key insights into how these factors
may be regulating specific oncogenic pathways. These are particularly important when dealing
with genomic aberrations that occur in non-gene-coding regions, such as seen with PVT1–MYC gene
fusions in Group 3 medulloblastomas [3]. Integrating miRNA–proteomic networks into our current
understanding of genomic abnormalities therefore provides a clearer picture of functional pathways
regulating tumor behavior and may refine future therapeutic interventions.
10. Proteomic Analysis of Medulloblastoma-Derived Exosomes
Exosomes are membrane-derived extracellular vesicles that are shown to influence various
cellular interactions. Intriguingly, tumor cells produce exosomes that can significantly influence
a number of cancer-related processes such as metastatic invasion, drug resistance, angiogenesis
and cellular growth [55]. Exosomes serve as an alternative intercellular trafficking mechanism
that enables exchange of molecules, including oncogenic proteins and nucleic acids, that could be
susceptible to extracellular degradation if released via classical secretory pathways. Initial studies
demonstrated the exosome-mediated transfer of biologically active oncogenic EGFRvIII proteins
from glioma cells into culture media and plasma of tumor xenograft-bearing mice [56]. Similarly,
elevated c-MYC RNA was found in exosomes isolated from mice harboring human medulloblastoma
xenotransplants [57]. Cultured medulloblastoma cells with amplified c-MYC had higher DNA/RNA
levels of this oncogene within exosomes compared to non-c-MYC-amplified cells [57]. It is suggested
that exosomes isolated from plasma or CSF of medulloblastoma patients may be used to decipher
molecular features underlying malignancy or reflect responses to therapy [57].
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Proteomics is a powerful tool to identify the functional role for exosomes in medulloblastoma.
Initial studies characterized the structure and expression of exosomal proteins from the
medulloblastoma cell line D283MED, and further demonstrated increased tumor cell proliferation
and migration when these exosomes were added to medulloblastoma cell lines [58]. The transcription
factor hepatocyte nuclear factor 4 α (HNF4A) was identified as having a possible role as a tumor
suppressor in this this cell line using pathway analysis of the exosomal proteins [58]. Subsequent
examination of these initial proteomic results, focusing on transcriptional regulators, found further
proteins that significantly influence downstream, cancer-related pathways (e.g., BRCA1, p53) [59].
It is abundantly clear that multiple post-transcriptional factors significantly restrict direct
correlations between genomic aberrations and resultant oncogenic behavior. In addition to this,
exciting new research now reveals the significance of extracellular vesicular release (exosomes) in
modulating cancer cell behavior, either through altering transcriptional pathways or directly through
proteomic signaling mechanisms. In this regard, proteomics is shedding new light into the influence of
miRNAs and the other exosomal components on tumor cell behavior and response to injury.
11. Conclusions
Quantitative proteomics has undergone rapid technological improvement over the past decade.
The majority of this growth has occurred in the context of tightly controlled experimental variables
and has not yet been extensively tested in the arena of clinical tissue samples or biofluids. Applied
proteomics carries the promise of visualizing the functional compartment of the cell and thus the
interface of cellular biology and cellular bioprocesses helping to focus on the link between genetic
changes and functional phenotypes and to identify potential therapeutic targets. Additionally,
this compartment is rich in therapeutic opportunities. For example, studies of protein modifications,
such as phosphoproteomics offer the ability to understand active signaling matrices and
compartment-based proteomics (e.g., membrane proteins) can identify antigens for targeted antibody-
and cell-based immunotherapies. This approach provides a platform for understanding the biology of
other cancers by providing a functional context to frame genomic abnormalities.
Currently, the proteomics field struggles with some significant challenges such as the lack of
bona fide housekeeping proteins for intercellular normalization, the dynamic range of detection
necessary to quantitate the entire proteome across its naturally occurring abundance range, and the
lack of sensitivity necessary to tackle intercellular tumor heterogeneity or rare biomarker detection
(e.g., peptides resulting from signature coding mutations). In cancer research, genomic discovery
platforms are remarkably capable, yet the data they provide is removed from the functional biology
they ultimately control. This fact creates a challenge in contextualizing the massive yield of findings.
Viewing the genomic landscape through the lens of proteomics may provide the necessary context by
identifying which genomic aberrations are translated to the functional compartment of the cell, thus
helping to discern the essential genomic features of a tumor. A rapid expansion of applied quantitative
proteomic capabilities is anticipated in the near future with implications for biological investigation,
drug target identification, and biomarker discovery.
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